Leverage Shares 2X Long FIX Daily ETF (BATS:FIXX – Get Free Report) was the recipient of a large drop in short interest during the month of September. As of September 30th, there was short interest totaling 2,984 shares, a drop of 39.7% from the September 15th total of 4,949 shares. Based on an average trading volume of 2,478 shares, the short-interest ratio is presently 1.2 days.
Insider Buying and Selling
In other Leverage Shares 2X Long FIX Daily ETF news, insider Shelia M. Violette sold 2,798 shares of the company’s stock in a transaction on Tuesday, August 25th. The stock was sold at an average price of $16.56, for a total value of $46,334.88. Following the transaction, the insider owned 127,771 shares of the company’s stock, valued at $2,115,887.76. This represents a 2.14% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CEO Jodie Pope Morrison sold 3,221 shares of the stock in a transaction on Tuesday, October 6th. The stock was sold at an average price of $8.32, for a total value of $26,798.72. Following the completion of the sale, the chief executive officer owned 340,038 shares in the company, valued at approximately $2,829,116.16. The trade was a 0.94% decrease in their position. The disclosure for this sale is available in the SEC filing. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last three months, insiders sold 22,054 shares of company stock valued at $320,397.
Leverage Shares 2X Long FIX Daily ETF Trading Down 7.1%
Shares of BATS:FIXX traded down $0.73 on Friday, hitting $9.56. 254 shares of the company’s stock were exchanged, compared to its average volume of 2,977. Leverage Shares 2X Long FIX Daily ETF has a 12 month low of $9.14 and a 12 month high of $15.92.
Homology Medicines, Inc was a clinical-stage biotechnology company focused on developing genetic medicines for patients with rare diseases. The company sought to use its proprietary human-derived adeno-associated virus vectors, known as AAVHSCs, to deliver gene therapies in vivo and address the underlying causes of inherited disorders.
Its development programs included HMI-103, an investigational gene therapy for phenylketonuria, as well as earlier programs targeting other rare diseases.
See Also
- Five stocks we like better than Leverage Shares 2X Long FIX Daily ETF
- Rocket Lab’s Neutron Delay Leaves Wall Street Bullish But Raises the Stakes for 2027
- ManpowerGroup Stock Sinks on Q3 Results, But Fundamentals Stay Solid
- Does the AI Selloff Put Alphabet’s Breakout in Doubt?
- Bank Earnings Are Mixed—These 2 ETFs Offer Very Different Paths to a Recovery
Receive News & Ratings for Leverage Shares 2X Long FIX Daily ETF Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Leverage Shares 2X Long FIX Daily ETF and related companies with MarketBeat.com's FREE daily email newsletter.
